133 related articles for article (PubMed ID: 28128648)
1. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
Goolsby Hunter A; Rosenblatt L; Patel C; Blauer-Peterson C; Anduze-Faris B
Curr Med Res Opin; 2017 May; 33(5):829-836. PubMed ID: 28128648
[TBL] [Abstract][Full Text] [Related]
2. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
LaMori J; Tandon N; Laliberté F; Germain G; Pilon D; Lefebvre P; Prabhakar A
J Med Econ; 2016; 19(4):364-73. PubMed ID: 26624985
[TBL] [Abstract][Full Text] [Related]
3. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
4. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
[TBL] [Abstract][Full Text] [Related]
5. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
7. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
8. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
9. Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study.
Jančorienė L; Rozentāle B; Tolmane I; Jēruma A; Salupere R; Buivydienė A; Valantinas J; Kupčinskas L; Šumskienė J; Čiupkevičienė E; Ambrozaitis A; Golubovska O; Moroz L; Flisiak R; Bondar B
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763696
[No Abstract] [Full Text] [Related]
10. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
[TBL] [Abstract][Full Text] [Related]
11. Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C.
Cholankeril G; Perumpail RB; Hu M; Skowron G; Younossi ZM; Ahmed A
Dig Dis Sci; 2016 Sep; 61(9):2505-15. PubMed ID: 27084385
[TBL] [Abstract][Full Text] [Related]
12. Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study.
Mendlowitz A; Bremner KE; Walker JD; Wong WWL; Feld JJ; Sander B; Jones L; Isaranuwatchai W; Krahn M
CMAJ Open; 2021; 9(3):E897-E906. PubMed ID: 34584004
[TBL] [Abstract][Full Text] [Related]
13. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.
Younossi ZM; Otgonsuren M; Henry L; Arsalla Z; Stepnaova M; Mishra A; Venkatesan C; Hunt S
J Viral Hepat; 2015 Feb; 22(2):137-45. PubMed ID: 24813350
[TBL] [Abstract][Full Text] [Related]
14. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain.
Sicras-Mainar A; Navarro-Artieda R; Sáez-Zafra M
Gastroenterol Hepatol; 2018 Apr; 41(4):234-244. PubMed ID: 29287992
[TBL] [Abstract][Full Text] [Related]
15. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.
McElroy HJ; Roberts SK; Thompson AJ; Angus PW; McKenna SJ; Warren E; Musgrave S
J Med Econ; 2017 Jan; 20(1):72-81. PubMed ID: 27552282
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
Pandya P; Rzouq F; Oni O
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):555-65. PubMed ID: 25835493
[TBL] [Abstract][Full Text] [Related]
18. In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections.
Campana B; Calabrese D; Matter MS; Terracciano LM; Wieland SF; Heim MH
J Viral Hepat; 2018 Mar; 25(3):262-271. PubMed ID: 29086446
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
[No Abstract] [Full Text] [Related]
20. HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE.
Castelo A; Mello CEB; Teixeira R; Madruga JVR; Reuter T; Pereira LMMB; Silva GF; Álvares-DA-Silva MR; Zambrini H; Ferreira PRA
Arq Gastroenterol; 2018; 55(4):329-337. PubMed ID: 30785514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
